



(11) **EP 0 797 999 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
 01.10.1997 Bulletin 1997/40

(51) Int Cl.<sup>6</sup> **A61K 38/22**  
 // C07K14/575, C12N15/16

(21) Application number: **97301996.3**

(22) Date of filing: **24.03.1997**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL**  
**PT SE**  
 Designated Extension States:  
**RO**

- Edwards, Mary Joanna  
 Indianapolis, Indiana 46206 (US)
- Plick, Michael John  
 Ashford, Connecticut 06278 (US)
- Rineis, Joseph Vincent, Jr.  
 Brownsburg, Indiana 46112 (US)

(30) Priority: **28.03.1996 US 14177**  
**05.04.1996 US 14961**

(71) Applicant: **ELI LILLY AND COMPANY**  
 Indianapolis, Indiana 46286 (US)

(74) Representative: Hudson, Christopher Mark et al  
 Lilly Industries Limited  
 European Patent Operations  
 Eri Wood Manor  
 Windlesham Surrey GU20 6PH (GB)

(72) Inventors:  
 • Beale, John Michael  
 Indianapolis, Indiana 46278-1863 (US)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) **Formulations of obesity protein**

(57) The present invention provides lyophilized compositions of an obesity protein. The compositions demonstrate remarkable stability and ease of manufacture and, significantly, are useful to prepare, stable pharmaceutical

formulations useful for treating patients in need thereof. Thus, the invention further provides methods of using such formulations for the treatment of obesity, and disorders associated with obesity such as diabetes, cardiovascular disease and cancer.

**EP 0 797 999 A2**

**BEST AVAILABLE COPY**